----

**SECURITIES        AND EXCHANGE COMMISSION**

**Washington,        D.C.  20549**

**______________________**

**FORM        10-QSB**

**[        X ] Quarterly Report under Section 13 or 15(d) of the Securities Exchange        Act of        1934**

**[   ]   Transition        Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of        1934**

**CANCER        THERAPEUTICS, INC.**

| Delaware                                                                                        |   | 20-1499421                                                         |
|-------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------|
| (State                  or Other Jurisdictionof                  Incorporation or Organization) |   | (IRS                  EmployerIdentification                  No.) |
|                                                                                            |   |                                                               |
| 10757                  South River Front Pkwy, Suite 125                                        |   |                                                               |
| South                  Jordan, Utah                                                             |   | 84095                                                              |
| (Address                  of Principal Executive Offices)                                       |   | (Zip                  Code)                                        |

|   | (801)                  816-2533                                       |   |
|--------|-----------------------------------------------------------------------|--------|
|   | Issuer’s                  Telephone Number, Including Area Code |   |
|   |                                                                  |   |

----

**APPLICABLE        ONLY TO ISSUERS INVOLVED IN BANKRUPTCY**

**PROCEEDINGS        DURING THE PRECEDING FIVE YEARS**

**APPLICABLE          ONLY TO CORPORATE ISSUERS**

----

**PART        I**

**FINANCIAL          INFORMATION**

| **ITEM                  1.** | **FINANCIAL                  STATEMENTS REQUIRED BY FORM                  10-QSB** |
|------------------------------|------------------------------------------------------------------------------------|

| **CONTENTS**                                               |
|-----------------------------------------------------------------|
| Balance                  Sheet                        | 4 |
| Statements                  of Operations             | 5 |
| Statements                  of Cash Flows             | 6 |
| Notes                  to the Financial Statements    | 7 |

----

| **CANCER                    THERAPEUTICS, INC.**                                                                |   |
|-----------------------------------------------------------------------------------------------------------------|--------|
| Balance                    Sheet                                                                                |   |
|                                                                                                            |   |   |   |
|                                                                                                            |   |   |   |
| ASSETS                                                                                                          |   |   |   |
|                                                                                                            |   | August                    31, |   |
|                                                                                                            |   | 2007 |   |
|                                                                                                            |   |   |   |
| CURRENT                    ASSETS                                                                               |   |   |   |
|                                                                                                            |   |   |   |
| Cash                    and cash equivalents                                                                    |   | $ | 1,950 |   |
|                                                                                                            |   |   |   |   |
| Total                    Current Assets                                                                         |   |   | 1,950 |   |
|                                                                                                            |   |   |   |   |
| TOTAL                    ASSETS                                                                                 |   | $ | 1,950 |   |
|                                                                                                            |   |   |   |   |
| LIABILITIES                    AND STOCKHOLDERS' DEFICIT                                                        |   |   |   |   |
|                                                                                                            |   |   |   |   |
| CURRENT                    LIABILITIES                                                                          |   |   |   |   |
|                                                                                                            |   |   |   |   |
| Accounts                    payable and accrued expenses                                                        |   | $ | 171,784 |   |
| Due                    to related parties                                                                       |   |   | 105,443 |   |
| Notes                    payable                                                                                |   |   | 50,000 |   |
| Notes                    payable - related parties                                                              |   |   | 164,794 |   |
|                                                                                                            |   |   |   |   |
| Total                    Current Liabilities                                                                    |   |   | 492,021 |   |
|                                                                                                            |   |   |   |   |
| STOCKHOLDERS'                    DEFICIT                                                                        |   |   |   |   |
|                                                                                                            |   |   |   |   |
| Common                    stock, $0.001 par value; 100,000,000                                                  |   |   |   |   |
|  shares                    authorized, 4,157,688 shares issued,                                            |   |   |   |   |
|  4,129,477                    shares outstanding                                                           |   |   | 4,158 |   |
| Additional                    paid-in capital                                                                   |   |   | 2,517,862 |   |
| Accumulated                    deficit                                                                          |   |   | (2,997,985 | ) |
| Common                    stock held in treasury, 28,211 shares at cost                                         |   |   | (14,106 | ) |
|                                                                                                            |   |   |   |   |
| Total                    Stockholders' Deficit                                                                  |   |   | (490,071 | ) |
|                                                                                                            |   |   |   |   |
| TOTAL                    LIABILITIES AND STOCKHOLDERS' DEFICIT                                                  |   | $ | 1,950 |   |
|                                                                                                            |   |   |   |   |
|                                                                                                            |   |   |   |   |
| The                    accompanying notes are an integral part of these financial                    statements |   |   |   |   |
|                                                                                                            |   |   |   |   |

----

| **CANCER                    THERAPEUTICS, INC.**                                                                |   |                                          |      |   |   |   |
|-----------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------|-----------|--------|--------|--------|
| Statements                    of Operations                                                                     |   |                                          |      |   |   |   |
|                                                                                                            |   |                                          |      |   |   |   |
|                                                                                                            |   |                                          |      |   |   |   |
|                                                                                                            |   | For                    the Three Months Ended |      |
|                                                                                                            |   | August                    31,                 |      |   |   |   |
|                                                                                                            |   | 2007                                          |      |   | 2006   |   |
|                                                                                                            |   |                                          |      |   |   |   |
| NET                    REVENUES                                                                                 |   | $                                             | -         |   |   | $      | 7,100 |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| OPERATING                    EXPENSES                                                                           |   |                                          |      |   |   |   |   |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| General                    and administrative                                                                   |   |                                          | 1,640     |   |   |   | 17,759 |   |
| Professional                    fees                                                                            |   |                                          | 11,450    |   |   |   | 11,250 |   |
| Gain                    on settlement of debt                                                                   |   |                                          | -         |   |   |   | (141,600 | ) |
| Gain                    on sale of assets                                                                       |   |                                          | (14,106   | )      |   |   | - |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| Total                    Operating Expenses                                                                     |   |                                          | (1,016    | )      |   |   | (112,591 | ) |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| INCOME                    FROM OPERATIONS                                                                       |   |                                          | 1,016     |   |   |   | 119,691 |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| OTHER                    EXPENSES                                                                               |   |                                          |      |   |   |   |   |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| Interest                    expense                                                                             |   |                                          | (5,028    | )      |   |   | (4,359 | ) |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| Total                    Other Expenses                                                                         |   |                                          | (5,028    | )      |   |   | (4,359 | ) |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| INCOME                    (LOSS) BEFORE INCOME TAXES                                                            |   |                                          | (4,012    | )      |   |   | 115,332 |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| INCOME                    TAX EXPENSE                                                                           |   |                                          | -         |   |   |   | - |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| NET                    INCOME (LOSS)                                                                            |   | $                                             | (4,012    | )      |   | $      | 115,332 |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| BASIC                    NET INCOME (LOSS) PER SHARE                                                            |   | $                                             | (0.00     | )      |   | $      | 0.03 |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| WEIGHTED                    AVERAGE NUMBER OF                                                                   |   |                                          |      |   |   |   |   |   |
| SHARES                    OUTSTANDING                                                                           |   |                                          | 4,148,284 |   |   |   | 4,097,688 |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |
| The                    accompanying notes are an integral part of these financial                    statements |   |                                          |      |   |   |
|                                                                                                            |   |                                          |      |   |   |   |   |   |

----

| **CANCER                    THERAPEUTICS, INC.**                                                                |   |                                          |    |   |   |   |
|-----------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------|---------|--------|--------|--------|
| Statements                    of Cash Flows                                                                     |   |                                          |    |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |
|                                                                                                            |   | For                    the Three Months Ended |    |
|                                                                                                            |   | August                    31,                 |    |   |   |   |
|                                                                                                            |   | 2007                                          |    |   | 2006   |   |
|                                                                                                            |   |                                          |    |   |   |   |
| CASH                    FLOWS FROM OPERATING ACTIVITIES:                                                        |   |                                          |    |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |
| Net                    income (loss)                                                                            |   | $                                             | (4,012  | )      |   | $      | 115,332 |   |
| Adjustments                    to reconcile net income (loss) to net                                            |   |                                          |    |   |   |   |   |   |
|  cash                    used by operating activities:                                                     |   |                                          |    |   |   |   |   |   |
| Gain                    on settlement of debt                                                                   |   |                                          | -       |   |   |   | (141,600 | ) |
| Gain                    on sale of assets                                                                       |   |                                          | (14,106 | )      |   |   | - |   |
| Changes                    in operating assets and liabilities:                                                 |   |                                          |    |   |   |   |   |   |
| Accounts                    receivable                                                                          |   |                                          | -       |   |   |   | - |   |
| Accounts                    payable and accrued expenses                                                        |   |                                          | 1,624   |   |   |   | 17,746 |   |
| Due                    to related parties                                                                       |   |                                          | 12,081  |   |   |   | 3,200 |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| Net                    Cash Used by Operating Activities                                                        |   |                                          | (4,413  | )      |   |   | (5,322 | ) |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| CASH                    FLOWS FROM INVESTING ACTIVITIES:                                                        |   |                                          | -       |   |   |   | - |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| CASH                    FLOWS FROM FINANCING ACTIVITIES:                                                        |   |                                          |    |   |   |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| Payments                    on notes payable - related parties                                                  |   |                                          | -       |   |   |   | (2,000 | ) |
| Proceeds                    from notes payable - related parties                                                |   |                                          | 5,350   |   |   |   | 9,000 |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| Net                    Cash Provided by Financing Activities                                                    |   | $                                             | 5,350   |   |   | $      | 7,000 |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| NET                    INCREASE IN CASH AND CASH EQUIVALENTS                                                    |   | $                                             | 937     |   |   | $      | 1,678 |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| CASH                    AND CASH EQUIVALENTS, BEGINNING OF PERIOD                                               |   |                                          | 1,013   |   |   |   | 1,552 |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| CASH                    AND CASH EQUIVALENTS, END OF PERIOD                                                     |   | $                                             | 1,950   |   |   | $      | 3,230 |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| SUPPLEMENTAL                    CASH FLOW INFORMATION                                                           |   |                                          |    |   |   |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| Cash                    Payments For:                                                                           |   |                                          |    |   |   |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| Interest                                                                                                        |   | $                                             | 421     |   |   | $      | 231 |   |
| Income                    taxes                                                                                 |   | $                                             | -       |   |   | $      | - |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |
| The                    accompanying notes are an integral part of these financial                    statements |   |                                          |    |   |   |   |   |   |
|                                                                                                            |   |                                          |    |   |   |   |   |   |

----

**CANCER        THERAPEUTICS, INC.**

| NOTE                  1 | BASIS                  OF FINANCIAL STATEMENT PRESENTATION |
|-------------------------|------------------------------------------------------------|

|   | The                  accompanying unaudited consolidated financial statements have been                  prepared by the Company pursuant to the rules and regulations of                  the                  Securities and Exchange Commission.  Certain information and                  footnote disclosures normally included in financial statements                  prepared in                  accordance with U.S. generally accepted accounting principles have                  been                  condensed or omitted in accordance with such rules and                  regulations.  The information furnished in the interim financial                  statements includes normal recurring adjustments and reflects all                  adjustments, which, in the opinion of management, are necessary                  for a fair                  presentation of such financial statements.  Although management                  believes the disclosures and information presented are adequate                  to make                  the information not misleading, it is suggested that these interim                  consolidated financial statements be read in conjunction with the                  Company’s audited financial statements and notes thereto included in its                  Form 10KSB filed on August 30, 2007.  Operating results for the                  three months ended August 31, 2007 are not necessarily indicative                  of the                  results to be expected for the year ending May 31,                  2008.   |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**ITEM        2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF        OPERATION**

| You                  should read the following discussion of the company's financial                  condition                  and results of operations in conjunction with the audited financial                  statements and related notes included in the filing of the company’s                  latest annual 10-KSB.  This discussion may contain                  forward-looking statements, including, without limitation, statements                  regarding our expectations, beliefs, intentions, or future strategies                  that                  are signified by the words "expects," "anticipates," "intends,"                  "believes," or similar language.  Actual results could differ                  materially from those projected in the forward looking                  statements.  You should carefully consider the information under                  the caption "Risk Factors" in this filing, in addition to the other                  information set forth in this report.  We caution you that                  Cancer Therapeutics’ business and financial performance is subject to                  substantial risks and                  uncertainties. |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Results        of Operations**

**Revenues.**

**Potential        Liability for a        Violation of the Securities Act of 1933**
*.*

**General        and Administrative        Expenses**

**Professional        Fees.**

**Gain        on Settlement of        Debt.  **

----

**Gain        on Sale of        Assets.  **

**Other        Expense**
**s**
**.**

**Off-Balance        Sheet Arrangements.**

**Personnel**

**Liquidity        and Capital Resources**

**FORWARD        LOOKING STATEMENTS AND RISK FACTORS**

**Forward        Looking Statements**

----

**RISK        FACTORS**

**Operating        Risks**

***We        May be Subject to        Liability for a Violation of the Securities Act of        1933.***

***We        have Defaulted Loan        Obligations.   ***

***We        Have Consistently        Operated at a Loss***
*.*

***We        have no Operating        Capital, and We Must Raise Additional Capital to Remain in        Business***
*.*

**Investment        Risks**

***Speculative        Investment***
**.**

----

***Securities        Class Action        Claims Based Upon Price        Fluctuation***
**.**

***No        Active        Market***
**.**

***No        Dividends***
**.**

***You        Could be Diluted from        the Issuance of Additional Common and Preferred        Stock.***

**ITEM        3.  CONTROLS AND PROCEDURES**

**PART        II**

**OTHER        INFORMATION**

| **ITEM                  1.** | **LEGAL                  PROCEEDINGS** |
|------------------------------|----------------------------------------|

----

| **ITEM                  2.** | **UNREGISTERED                  SALES OF EQUITY SECURITIES AND USE OF                  PROCEEDS** |
|------------------------------|---------------------------------------------------------------------------------------------------|

| **ITEM                  3.** | **DEFAULTS                  UPON SENIOR SECURITIES** |
|------------------------------|------------------------------------------------------|

| **ITEM                  4.** | **SUBMISSION                  OF MATTERS TO A VOTE OF SECURITY                  HOLDERS** |
|------------------------------|-------------------------------------------------------------------------------------------|

| **ITEM                  5.** | **OTHER                  INFORMATION** |
|------------------------------|----------------------------------------|

----

| **ITEM                  6.** | **EXHIBITS** |
|------------------------------|--------------|

**INDEX        TO EXHIBITS**

| **Exhibit****Number** |   |  **Title                  of Document**                                                                                   |
|-----------------------|--------|--------------------------------------------------------------------------------------------------------------------------------|
| 3.1                   |   | Certificate                  of Incorporation of Cancer Therapeutics, Inc., a Delaware corporation.                  (1)       |
| 3.2                   |   | Bylaws                  of Cancer Therapeutics, Inc., a Delaware corporation.                  (2)                             |
| 4.1                   |   | Form                  of Common Stock Certificate. (3)                                                                         |
| 5.1                   |   | Opinion                  of Kenneth I. Denos, P.C., Attorney at Law (including consent).                  (4)                  |
| 10.1                  |   | Warrant                  Issued to Healthcare Enterprise Group, Inc. (5)                                                       |
| 10.2                  |   | Engagement                  Agreement between the Registrant and John Thomas, Esq.                  (6)                        |
| 10.3                  |   | Accounting                  Services Agreement between the Registrant and Chene C. Gardner                  (7)                |
| 10.4                  |   | Engagement                  Agreement between the Registrant and Kenneth I. Denos, P.C.                  (8)                   |
| 10.5                  |   | Advisory                  Agreement between the Registrant and Industrial Management & Equity                  Limited (9) |
| 10.6                  |   | Form                  of Subscription Agreement between Cancer Therapeutics and Investors                  (10)                |
| 10.7                  |   | Escrow                  Agreement (11)                                                                                         |
| 10.8                  |   | Summary                  of Oral Agreement between the Registrant and Robert K. Oldham                  (12)                   |
| 10.9                  |   | Summary                  of Oral Agreement between the Registrant and Walter Lewko                  (13)                       |
| 10.10                 |   | Appointment                  Letter for Mike K. Low (14)                                                                       |
| 10.11                 |   | Specimen                  Contract with John D. Archibold Memorial Hospital, Inc.                  (15)                        |
| 23.1                  |   | Consent                  of Bouwhuis, Morrill and Company, LLC. (16)                                                           |
| 23.2                  |   | Consent                  of Kenneth I. Denos, P.C. (Filed as part of Exhibit 5.1).                  (17)                       |
| 99.1                  |   | Senate                  Bill 341 (18)                                                                                          |

----

| 99.2 |   | Certification                  by Chief Executive Officer and Chief Financial Officer, Chene Gardner,                  pursuant to Section 302 of the Sarbanes-Oxley Act of                  2002. |
|------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.4 |   | Certification                  by Chief Executive Officer and Chief Financial Officer, Chene Gardner,                  pursuant to Section 906 of the Sarbanes-Oxley Act of                  2002. |

| (1)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (7)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (8)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (9)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (10)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (11)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (12)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (13)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (14)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (15)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (16)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (17)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (18)   | Filed                  as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed                  effective by the Commission on May 15,                  2006. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**SIGNATURES**

|   | CANCER                  THERAPEUTICS, INC. |
|--------|--------------------------------------------|

----